s6y

NewcelX Ltd.

Ticker
NCEL
CIK
1783036
Industry
Pharmaceutical Preparations
Formerly
NLS Pharmaceutics Ltd.

Financials 4

  1. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2024
  2. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2023
  3. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2022
  4. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2020

Ownership 32

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. 3 Initial statement of beneficial ownership of securities
  7. 3 Initial statement of beneficial ownership of securities
  8. 3 Initial statement of beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 3 Initial statement of beneficial ownership of securities

All 32 ownership filings

Prospectus 30

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  3. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  4. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  5. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  6. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  7. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  8. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  9. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  10. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

All 30 prospectus filings

Other 354

  1. D Exempt (Private) Offering
  2. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  3. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  4. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  5. EFFECT Notice of Effectiveness
  6. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
  7. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  8. EFFECT Notice of Effectiveness
  9. D Exempt (Private) Offering
  10. F-3 Registration statement for specified transactions by certain foreign private issuers

All 354 other filings